CASE PRESENTATION {#s1}
=================

A 73-yr-old female, with a remote history of light smoking, was diagnosed with stage 2B non-small-cell lung carcinoma (NSCLC). The lung mass was removed via wedge resection and morphologically examined in its entirety. Histologic examination showed moderately differentiated adenocarcinoma with mucinous and micropapillary histology with focal microscopic visceral pleural invasion and lymphovascular invasion without lymph node involvement. All staging scans were negative for distant metastases. Targeted *EGFR* analysis and fluorescence in situ hybridization (FISH) of the tumor showed an *ALK* rearrangement. The patient completed four cycles of chemotherapy with carboplatin/pemetrexed and notably did not receive therapy with an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI).

The patient subsequently presented 2 years later with progressive abdominal enlargement and multiple liver metastases without evidence of disease in the thoracic cavity. Biopsy of a liver lesion showed small-cell carcinoma (strongly positive for TTF-1, CK7, and Synaptophysin and negative for CK20) that was morphologically distinct from the original NSCLC ([Fig. 1](#MCS002394BALF1){ref-type="fig"}).

![(*A*) Fine-needle aspiration (FNA) of liver metastasis at time of recurrence (Pap stain). (*B*) MGG stain. (*C*) Strong membranous staining with Synaptophysin (27G12, Leica). (*D*) Strong nuclear staining with TTF-1 (SPT24, Leica). The tumor also demonstrated strong cytoplasmic staining for CK7 (RN7, Leica) and was negative for CK20 (Ks20.8, Leica).](MCS002394Bal_F1){#MCS002394BALF1}

Technical Analysis {#s1a}
------------------

The metastatic tumor was analyzed for the *ALK* fusion and DNA mutation analysis. ALK rearrangement by FISH was unsuccessful because of technical failure and was thereby determined positive with qualitative immunohistochemistry (IHC) validated to detect ALK expression as a surrogate marker of ALK rearrangement in formalin-fixed paraffin-embedded (FFPE) tissue. The fusion was more specifically confirmed with targeted next-generation sequencing (NGS) of the tumor RNA as the EML4 exon 20 to ALK exon 20 fusion ([Fig. 2](#MCS002394BALF2){ref-type="fig"}).

![(*A*) Hematoxylin and eosin (H&E)-stained section of liver core needle biopsy showing metastatic small-cell carcinoma. (*B*) ALK IHC (D5F3, Ventana, performed according to manufacturer\'s instructions) demonstrated the tumor cells to be strongly and diffusely positive in a combined cytoplasmic and membranous pattern. (*C*) RNA NGS data showing the *EML4* exon 20--*ALK* fusion. Integrated genome viewer (IGV) sequence alignments at the point of mRNA fusion show *ALK* exon 20 sequence fused to the *EML4* exon 20 genomic location (*left* panel) and *EML4* exon 20 sequence fused to *ALK* exon 20 genomic location (*right* panel). Schematic of the predicted *ELM4*--*ALK* fusion mRNA (*bottom*).](MCS002394Bal_F2){#MCS002394BALF2}

The DNA from the metastatic tumor was also submitted for targeted genomic profiling for single-nucleotide variants and insertion/deletion mutations using an NGS assay that is clinically validated for use in solid tumors (Illumina MiSeq). The assay uses an Agilent Sure Select XT target probe library custom designed to capture exons and selected intronic regions of 29 genes: *AKT1*, *ALK*, *BRAF*, *CDKN2A*, *CTNNB1*, *DDR2*, *EGFR*, *ERBB2*, *ESR1*, *FGFR1*, *FGFR2*, *GNA11*, *GNAQ*, *IDH1*, *IDH2*, *KIT*, *KRAS*, *MAP2K1*, *MAP2K2*, *MAPK1*, *MET*, *MTOR*, *NRAS*, *PDGFRA*, *PIK3CA*, *PTEN*, *RET*, *ROS1* and *STK11*. Targeted NGS of the tumor DNA did not show any additional clinically actionable mutations. The clinical assays requested did not include analysis of copy number variation, nor did the NGS capture content analyze RB1.

The original tumor was resected at an outside center not affiliated with the University of Vermont Medical Center, and although completely submitted for morphologic evaluation, the tissue was not available for additional testing utilizing NGS ([Table 1](#MCS002394BALTB1){ref-type="table"}).

###### 

Genomic findings

  Gene/genomic location   Chr   HGVS DNA ref                                                HGVS protein ref   Variant type       Predicted effect   Allele frequency   Target coverage
  ----------------------- ----- ----------------------------------------------------------- ------------------ ------------------ ------------------ ------------------ -----------------
  *ALK*                   2     t(2;2)(p23;p21)(hg19 Chr 2:g.42552694::oChr 2:g.29446394)   n/a                EML4--ALK fusion   Oncogenic          n/a                301×

Variant Interpretation {#s1b}
----------------------

The small-cell carcinoma with retained *ALK* rearrangement was ultimately classified as metastatic recurrent NSCLC that had undergone small-cell transformation. After six cycles of carboplatin and etoposide, computed tomography (CT) scans showed a mixed response with stable bony lesions but innumerable liver lesions and central nervous system involvement. Alectinib was then initiated but with progressive disease at 3 months, it was discontinued with transition to comfort care.

NSCLC transformation to small-cell lung cancer is a rare phenomenon that has been well-described in *EGFR*-mutant cancers. This transformation typically arises in the setting of treatment with EGFR-targeted TKI therapy and is considered to be a therapeutic resistance mechanism ([@MCS002394BALC14]; [@MCS002394BALC6]; [@MCS002394BALC1]; [@MCS002394BALC4]; [@MCS002394BALC7]; [@MCS002394BALC9]; [@MCS002394BALC13]; [@MCS002394BALC3]). Currently, there are only two published case reports that describe the presence of an *ALK* rearrangement in small-cell carcinoma ([@MCS002394BALC11], [@MCS002394BALC12]). One of these reports describes a tumor with mixed histopathology composed of a small-cell component and an adenocarcinoma component; however, unlike our case, *ALK* fusion was only detected in the small-cell component and the clinical therapeutic experience with TKI therapy was not addressed ([@MCS002394BALC11]).

The case presented herein is unique because the original tumor was completely resected with a complete histologic examination that excluded tumor heterogeneity with a small-cell component, and the patient was not treated with ALK-targeted therapy before undergoing small-cell transformation. This morphologic transformation in a tumor that originally did not exhibit a small-cell component lends support to the hypothesis that both tumor phenotypes, small-cell and non-small-cell, may arise from the same cancer progenitor cell. ([@MCS002394BALC2]; [@MCS002394BALC7]; [@MCS002394BALC3]). Tumor progression of the *ALK* fusion--positive transformed tumor on a second-generation TKI suggests that progression was more likely driven by genomic alterations more commonly identified in small-cell carcinoma rather than by the *ALK* fusion classically associated with NSCLC. Biopsy material from only one of many metastatic sites was evaluated and uniformly showed small-cell carcinoma. Although this precludes definitive exclusion of an adenocarcinoma component in the metastatic disease, the patient progressed nonetheless on both conventional chemotherapy and ALK TKI therapy.

Small-cell carcinoma, which typically occurs in heavy smokers and is characterized by aggressive growth and poor prognosis, has a high prevalence of mutations in *TP53* and *RB1* ([@MCS002394BALC5]; [@MCS002394BALC8]; [@MCS002394BALC10]). Additionally, integrative genomic analyses have implicated alterations in genes that encode histone-modifying enzymes including *CREBBP*, *EP300*, and *MLL* along with *SOX2* amplification ([@MCS002394BALC8]). Thus, although numerous recurrent genomic alterations have been documented in de novo small-cell carcinoma, *ALK* rearrangement currently is not described in the typical genomic profile of this tumor type.

SUMMARY {#s2}
=======

This case provides evidence that small-cell transformation of *ALK*-rearranged NSCLC can occur without selective pressure of targeted therapy and suggests these transformed tumors will not be sensitive to *ALK*-directed TKI therapy. It also demonstrates that transformation can occur after a relatively long, posttherapeutic disease-free interval. This supports a previous observation in transformed, TKI-treated *EGFR*-mutant NSCLC that small-cell transformation of NSCLC despite "targetable mutations" is associated with a relatively poor prognosis compared to nontransformed conventional small-cell carcinoma of the lung ([@MCS002394BALC3]). Moreover, progression of metastatic disease despite targeted therapy warrants consideration for therapeutic planning in the scenario of small-cell transformation given that it is hypothesized in this case that the genomic profile driving the tumor progression was not the *ALK* fusion. Lastly, this case shows there is diagnostic value in performing *ALK* fusion analysis in cases that are suspicious for small-cell transformation of a tumor originally diagnosed as *ALK* fusion--positive NSCLC as this ancillary information may provide insight into whether two morphologically distinct tumors share a common lineage. Additional clinical experience and more comprehensive functional genomic analysis of similarly transformed tumors are warranted to further evaluate these hypotheses and observations.
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Database Deposition and Access {#s3a}
------------------------------

The variant was submitted to ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession number SCV000676940.
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